Back to Results
First PageMeta Content
Auditing / Corporate governance / Regulation S-K / United States corporate law / Form 10-K / Angiogenesis / Aurora B kinase / Protein kinase inhibitor / U.S. Securities and Exchange Commission / SEC filings / United States securities law / Financial regulation


A Clinical Development CompanyForm 10-K EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company focused on developing
Add to Reading List

Document Date: 2014-05-14 13:07:09

Open Document

File Size: 674,69 KB

Share Result on Facebook

Company

Clinical Development Company / Board EntreMed Inc. / EntreMed Inc. / The NASDAQ Stock Market LLC / Indicate / K EntreMed Inc. / Nasdaq Capital Market / OVERVIEW EntreMed Inc. / /

Currency

USD / /

Event

FDA Phase / Reorganization / Company Listing Change / /

Facility

Medical Center Drive / CLINICAL PROGRAMS Our pipeline / /

IndustryTerm

treatment of cancer / pharmaceutical / healthcare / biopharmaceutical industry / /

MedicalCondition

leukemia / tumor / both solid and hematological malignancies / cancer / advanced cancers / multiple myeloma / disease / rheumatoid arthritis / solid tumors / human cancers / ovarian and colorectal cancer / inflammatory diseases / /

Organization

SECURITIES AND EXCHANGE COMMISSION WASHINGTON / D. C. / I.R.S. / U.S. Securities and Exchange Commission / /

Person

Aurora B. Aurora / Michael M. Tarnow / /

/

Position

Governor / Executive Chairman / Director Independence / Executive / Principal Accountant / /

Product

ENMD-1198 / ENMD-2076 / Panzem® / MKC-1 / /

URL

www.sec.gov / /

SocialTag